CHINA PHARMA HOLDINGS, INC.

Listed Company

CPHICIK 0001106644NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$4.14M

Net Income

$-3.20M

Total Assets

$31.00M

Equity

$22.74M

Shares Out

40.52M

Op. Cash Flow

$148.3K

Business

CHINA PHARMA HOLDINGS, INC. is a Nevada holding company that operates through its wholly owned subsidiary Helpson to develop, manufacture and market pharmaceutical and healthcare products in China. It offers prescription pharmaceuticals in forms including injectables, tablets, capsules and oral solutions, as well as healthcare and protective products such as sanitizers and masks. Its operations are organized around generic drugs (basic and first-to-market), modern Traditional Chinese Medicines and comprehensive healthcare product lines. The company sells primarily within the PRC through provincial and municipal pharmaceutical distributors to hospitals and OTC pharmacies.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	4	5	7	8	10
Cost of revenue	4	7	7	9	9
Gross loss	−131,950	−2	−281,085	−493,916	349,270
Selling expenses	375,786	528,824	780,328	1	1
General and administrative expenses	2	2	1	2	2
Research and development expenses	280,901	283,942	240,080	185,858	318,964
Credit (gains) losses	−1,018	5,702	−15,757	−93,851	−255,215
Total operating expenses	3	3	2	3	3
Loss from operations	−3	−5	−3	−4	−3
Research and development subsidy	151,556	—	—	—	—
Interest income	2,003	6,641	6,602	—	—
Interest expense	−102,037	−154,140	−333,600	—	—
Net other income (expense)	51,522	−147,499	−326,998	−423,864	−538,966
Loss before income taxes	−3	−5	−3	−4	−3
Income tax expense	—	—	—	—	—
Net loss	−3	−5	−3	−4	−3
Other comprehensive income (loss) - foreign currency translation adjustment	263,004	−132,412	−121,011	−990,764	218,383
Comprehensive loss	−3	−5	−3	−5	−3
Loss per share, basic (in Dollars per share)	−0.74	−2.71	−0.91	−3.78	−0.74
Loss per share, diluted (in Dollars per share)	−0.74	−2.71	−0.91	−3.78	−0.74
Weighted average shares outstanding (in Shares)	4	2	3	1	5

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	300,000	626,879	1	2	5
Bankers acceptances	—	18,642	65,915	13,784	91,362
Trade accounts receivable, less allowance for credit losses of $13,023 and $13,587,182, respectively	241,412	232,140	504,448	421,531	—
Other receivables, less allowance for doubtful accounts of $32,153 and $28,447, respectively	49,261	30,286	157,944	29,139	—
Advances to suppliers	6,831	14,960	2,013	444,637	471
Inventories	2	2	4	3	3
Prepaid expenses	82,368	81,328	110,258	77,697	58,792
Total Current Assets	2	3	6	6	9
Property, plant and equipment, net	4	5	7	10	13
Right-of-use assets	181,828	38,298	116,610	39,046	127,958
Intangible assets, net	24	7	3	2	147,841
TOTAL ASSETS	31	15	16	18	23
Trade accounts payable	891,083	225,106	966,420	667,082	926,749
Accrued expenses	350,643	247,159	298,829	404,807	298,452
Other payables	3	2	2	2	2
Contract liabilities	111,580	162,208	90,507	520,295	210,028
Borrowings from related parties	1	1	1	—	—
Lease liabilities	71,628	39,323	77,727	40,445	85,282
Current portion of lines of credit	2	1	1	2	4
Total Current Liabilities	7	5	7	13	11
Lines of credit, net of current portion	—	1	1	—	—
Lease liabilities net of current portion	111,548	—	39,910	—	44,181
Deferred tax liability	747,805	731,202	742,114	754,698	824,407
Total Liabilities	8	7	9	13	17
Commitments and Contingencies (Note 15)	—	—	—	—	—
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	—	—	—	—	—
Common stock, $0.001 par value; 500,000,000 shares authorized; 15,522,002 shares and 3,261,911 shares issued and outstanding, respectively	15,522	3,262	10,625	1,498	47,340
Additional paid-in capital	59	41	35	29	26
Securities purchase agreement receivable	−180,000	−180,000	—	—	—
Accumulated deficit	−47	−44	−39	−36	−32
Accumulated other comprehensive income	12	11	11	12	13
Total Stockholders Equity	23	8	7	4	6
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	31	15	16	18	23

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	2	3	3	3	3
Depreciation of right of use assets	75,534	58,931	—	—	—
Accounts written off to allowance for credit losses	−14	—	—	—	—
Financial expense	3,472	2,204	—	—	—
Provision to write down inventories to net realizable value	549,218	450,738	—	—	—
Trade accounts and other receivables	13	−197,708	−938,021	−170,194	−545,534
Advances to suppliers	8,334	−13,099	437,431	−459,959	—
Inventories	589,761	2	−17,058	689,104	1
Trade accounts payable	650,309	−733,916	312,045	−187,734	−332,779
Other payables and accrued expenses	465,753	431,215	257,778	692,190	415,309
Contract liabilities	−53,444	73,716	−423,261	339,659	−520,414
Prepaid expenses	793	27,565	−25,089	−24,722	—
Net Cash Provided by / (Used in) Operating Activities	148,261	−406,063	−699,686	−409,545	−249,838
Purchases of property, plant and equipment, net	−59,324	−38,411	−11,517	−401,964	−438,055
Advances for intangible assets	−77,927	−253,307	—	—	—
Net Cash Used In Investing Activities	−137,251	−291,718	−11,517	−401,964	−438,055
Payments of line of credit	−1	−492,761	−1	−2	−3
Proceeds from lines of credit	699,996	492,761	2	564,965	4
Proceeds from related party	261,070	27,353	30,572	28,962	1
Principal payments on finance lease liabilities	−78,750	−61,135	—	—	—
Net Cash Used In Financing Activities	−294,027	−33,782	73,145	−2	5
Effect of Exchange Rate Changes on Cash	1,250	−65,396	—	—	—
Net Decrease in Cash and Cash Equivalents	−281,767	−796,959	−606,133	−3	4
Cash paid for income taxes	—	—	—	—	—
Cash paid for interest	74,765	86,765	92,439	141,797	218,232
Issuances of stock for intangible assets	18	4	2	2	1
Right of Use Assets obtained in exchange for operating lease obligations	214,708	—	—	—	—
Conversions of Note Payable and interest to common stock	—	1	2	—	—
Issuance of common for securities purchase agreement	—	180,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro